MDB Capital Holdings, LLC (NASDAQ:MDBH – Get Free Report) was the recipient of a significant decrease in short interest in the month of January. As of January 30th, there was short interest totaling 2,107 shares, a decrease of 68.9% from the January 15th total of 6,782 shares. Based on an average daily trading volume, of 9,238 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the shares of the stock are short sold. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 9,238 shares, the short-interest ratio is currently 0.2 days.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (d)” rating on shares of MDB Capital in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.
Get Our Latest Stock Report on MDB Capital
Institutional Inflows and Outflows
MDB Capital Stock Performance
MDBH traded up $0.09 during trading on Wednesday, reaching $3.19. The stock had a trading volume of 11,447 shares, compared to its average volume of 8,044. The business has a 50-day moving average of $3.39 and a 200-day moving average of $3.55. MDB Capital has a one year low of $3.00 and a one year high of $7.98. The stock has a market cap of $32.30 million, a PE ratio of 3.42 and a beta of 1.09.
MDB Capital (NASDAQ:MDBH – Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.46) earnings per share (EPS) for the quarter. The business had revenue of $1.42 million during the quarter.
About MDB Capital
MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business.
See Also
- Five stocks we like better than MDB Capital
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for MDB Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDB Capital and related companies with MarketBeat.com's FREE daily email newsletter.
